Skip to main content

Advertisement

Table 5 SF-36 component scores throughout the study (mean ± sd) (ES: effect sizes)

From: Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study

  baseline week 12 week 24 P
PF (physical function) 27.2 ± 18.4 29.2 ± 16.5 36.0 ± 21.4** = 0.0079
ES   -0.11 -0.48  
RP (role physical) 2.56 ± 12.6 8.33 ± 25.2 11.54 ± 28.0* = 0.0657
ES   -0.46 -0.71  
BP (bodily pain) 10.9 ± 14.4 18.2 ± 17.9* 24.2 ± 20.6*** <0.0001
ES   -0.51 -0.92  
GH (global health) 26.3 ± 17.9 28.4 ± 18.5 29.6 ± 17.4 = 0.4321
ES   -0.12 -0.18  
VT (vitality) 13.6 ± 13.4 18.7 ± 19.4 19.9 ± 18.6* = 0.0301
ES   -0.38 -0.47  
SF (social function) 35.6 ± 27.4 41.0 ± 28.5 42.2 ± 29.9 = 0.2150
ES   -0.20 -0.26  
RE (role emotional) 19.7 ± 32.2 24.8 ± 38.8 29.1 ± 39.9 = 0.3293
ES   -0.16 -0.29  
MH (mental health) 31.5 ± 21.5 38.1 ± 21.3 42.8 ± 24.6** = 0.0023
ES   -0.31 -0.53  
  1. *: p < 0.05, **: p < 0.01 and ***: p < 0.001 in relation to baseline (Dunnett's post-test). Bold: large effect sizes.